Director · RECURSION PHARMACEUTICALS, INC. · RECURSION PHARMACEUTICALS, INC. — Class B Common Stock
Side
C
Value
—
Shares
60.0K
Price
—
Executed
Jan 5, 2026
Disclosed
Jan 7, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 5 executedJan 7, 2026 disclosed
RXRX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Derivative conversion — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 1.3% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
4 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
RECURSION PHARMACEUTICALS, INC. — Class B Common Stock
Ticker
RXRX
Shares
60.0K
Price per share
$0
Execution date (reported)
Jan 5, 2026
Owned after transaction
4.66M shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
2
What this establishes
Gibson Christopher filed this Form 4 reporting a derivative conversion of RXRX on Jan 5, 2026. It became public on Jan 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Gibson Christophercik:0001856369
Issuer
RECURSION PHARMACEUTICALS, INC.cik:0001601830
Revision history · 0
No field has changed since this record was first ingested.
